Tag Archives: Roche’s

Roche’s Tecentriq gets a green light to challenge Bayer with first-in-class liver cancer nod

After years of having the previously untreated liver cancer market all to itself, Bayer’s Nexavar is getting its first major competition—and it’s coming from Roche’s Tecentriq. The FDA Friday cleared a combination of the checkpoint inhibitor and fellow Roche med Avastin for previously untreated patients with hepatocellular carcinoma, the most common form of the disease.… Read More »

Roche’s Tecentriq nabs a solo OK in first-line lung cancer. But will it gain traction?

It was a long run, but Merck’s Keytruda finally has some company in the previously untreated non-small cell lung cancer monotherapy department. Whether that company represents any real threat to its market share, however, remains to be seen. The FDA Monday green-lighted Roche’s Tecentriq on its own for newly diagnosed, metastatic patients without EGFR or… Read More »